Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study).
The goal of this clinical research study is to learn if dasatinib can help to control ALL when given with the standard of care and/or a stem cell transplant. The safety of this drug will also be studied.
Treatment Location: N/A
To test whether the relapse-free survival after allogeneic stem cell transplantation among Philadelphia chromosome positive and/or BCR/ABL positive acute lymphblastic lekemia (ALL) patients given an intensive short-term chemotherpay regimen of hyper-CVAD in combination withte tryrosine kinase inhibitor dasatinib is sufficiently high to warrant further investigation To test whether the continous complete remission rate for previousl y untreated Philadelphia chromosome positive and/or BCR/ABL positive acute lymphoblastic (ALL) patients given an intensive short-term chemotherapy regimen of hyper-CVAD in combination with the tyrosine inhibitor dasatinib is sufficiently hight to warrant Phase III investigation. To investigate in a preliminary manner the relative effectiveness of minimum residual disease (MRD) detection using rel-time quantities polymerase chain reaction (PCR) for BCR/ABL versus flow cytomerty (FC) to predict the outcome of patients treated by the hyper-CVAD + dasatinib regimen and/or allogeneic stem cell transplant. To estimate the frequency and severity of toxicities of the intensive short-term chemotherapy regimen in these patients. To estimate the overall survival of all patients on this study.
IRB Review and Approval Date: 12/01/2010
Recruitment Status: Not Accepting
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: